



December 5, 2006

## **LIFEVANTAGE CORPORATION ANNOUNCES ADDITIONAL STUDIES INVOLVING PROTANDIM®**

DENVER, Colorado – Lifevantage Corporation, formerly Lifeline Therapeutics, Inc. (OTCBB: LFLT), maker of Protandim®, announced today that Protandim® has been made available to independent investigators engaged in human clinical and laboratory studies designed to investigate the ability of Protandim® to decrease oxidative stress in disease models. Oxidative stress is the cumulative cell damage caused by free radicals that occurs as a person ages, when subjected to environmental stresses or as an associated factor in certain illnesses. The areas of investigation include heart disease, liver disease, asthma, photoaging of the skin, osteoarthritis, metabolic syndrome, and muscular dystrophy. These independently funded investigations are being conducted at institutions that include the following:

The University of Colorado Health Sciences Center  
The University of Florida  
The University of Kentucky  
Denver Health Medical Center  
Vanderbilt University  
The University of Michigan  
Sahlgrenska University Hospital, Goteborg, Sweden  
Louisiana State University Health Science Center  
University of Toronto

### **About Protandim®**

Protandim® is a patent-pending dietary supplement that increases the body's natural antioxidant protection by inducing two protective enzymes, superoxide dismutase (SOD) and catalase (CAT). These naturally occurring enzymes become overwhelmed by free radicals as we get older. Oxidative stress (cell damage caused by free radicals) occurs as a person ages, when subjected to environmental stresses or as an associated factor in certain illnesses. TBARS are laboratory markers for oxidative stress in the body. Data from a peer-reviewed, published scientific study in men and women, sponsored by Lifevantage, show that after 30 days of taking Protandim®, the level of circulating TBARS decreased an average of 40 percent, with this decrease shown to be maintained at 120 days. Protandim® strengthens a person's defenses against oxidative stress by increasing the body's natural antioxidant enzymes. For more information, please visit the Protandim® product web site at [www.protandim.com](http://www.protandim.com).

### **About Lifevantage Corporation**

Lifevantage Corporation markets Protandim®. Lifevantage is committed to helping people achieve health and wellness for life. For more information, please visit the Company's web site at [www.Lifelinetherapeutics.com](http://www.Lifelinetherapeutics.com).

Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, applicable common law and Securities and Exchange Commission rules. The Company uses the words "anticipate," "believe," "could," "should," "estimate," "expect," "intend," "may," "predict," "project," "plan," "target" and similar terms and phrases, including references to assumptions, to identify forward-looking statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties are difficult to predict accurately and may be beyond the control of the Company. The following factors are among those that may cause actual results to differ materially from our forward-looking statements: government regulators and regulations could adversely affect our business; future laws or regulations may hinder or prohibit the production or sale of our existing product and any future products; unfavorable publicity could materially hurt our business and the value of your investment; the Company's ability to protect our intellectual property rights and the value of our product; and the illiquidity of our common stock. These and other additional risk factors and uncertainties are discussed in greater detail in the Company's Annual Report on Form 10-KSB under the caption "Risk Factors", and in other documents filed the Company from time to time with the Securities and Exchange Commission. Forward-looking statements made by the Company in this news release or elsewhere speak only as of the date made. New uncertainties and risks come up from time to time, and it is impossible for the Company to predict these events or how they may affect the Company. The Company has no duty to, and does not intend to, update or revise the forward-looking statements in this news release after the date it is issued. In light of these risks and uncertainties, investors should keep in mind that the results, events or

developments disclosed in any forward-looking statement made in this news release may not occur.

# # #

CONTACTS:

Lifevantage Corporation  
Stephen K. Onody, CEO  
Gerald J. Houston, CFO  
Telephone: 720-488-1711  
Fax: 303-565-8700